Small human study

CJC-1295

Growth-hormone and IGF-1 signaling in small human studies. It is not an FDA-approved medicine, and there are no large outcome trials.

15-second reel. It plays silently on a loop.

What it is

CJC-1295 is a growth-hormone-releasing hormone analogue — a GH-axis tool, not a tissue-repair peptide. It was designed as a long-acting form that binds albumin. The research question is whether it can raise growth hormone and, downstream, IGF-1. The reel says it in one line — a peptide studied for the body’s growth-hormone signal. Human data are limited. This is not a casual add-on. The published human studies used that long-acting (DAC) form. Many products discussed online are a shorter-acting “no-DAC” analog, which is not automatically the same compound.

Studied for

  • Growth-hormone and IGF-1 signaling, in small studies of healthy adults.
  • The pituitary GH axis, which is the pathway those studies measured.
  • Growth in mice missing the GHRH signal, which is animal biology, not a human outcome.

The evidence

Small human study. Short trials in healthy adults found that the long-acting (DAC) form can raise growth hormone and IGF-1, and that the usual pulsatile pattern of growth-hormone release was still present. Those were small, short studies of hormone levels, not trials of muscle gain, fat loss, injury repair, or long-term safety. It is not an FDA-approved medicine. That is a different record from tesamorelin, which has a formal approved indication. Cautions that apply to the growth-hormone and IGF-1 axis, including questions about insulin and cancer risk, belong in any serious discussion of this axis, and that discussion belongs with a physician.

What this page will not do

  • We do not give a dose, a route, a cycle, or a place to buy it.
  • A rise in growth hormone or IGF-1 in a short volunteer study is not evidence of a body-composition or anti-aging result.
  • The long-acting form studied in those papers is not automatically the same as products labeled CJC-1295 without DAC.

Still open

  • Whether large human trials with clinical outcomes and long-term safety data get published.
  • How questions about IGF-1, insulin, and cancer risk apply to a real person — that is a physician’s conversation, not a conclusion of this page.
  • How to keep online product names separate from the specific analog that was actually studied.

Educational content only. This page does not diagnose, treat, cure, or prevent anything, and it is not a dose. Talk with a licensed physician before starting, stopping, or changing any medication. Library reviewed November 2026.